When patients use sulfonylureas as medicine to control their type 2 DM, the risk of hypoglycemia needs to be considered, mainly because of the decreased clearance of insulin and oral hypoglycemic drugs and impaired renal gluconeogenesis [32]. This evidence concerns the gene INS and Hypoglycemia.